sorafenib has been researched along with Cardiovascular Stroke in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arain, S; Balanescu, DV; Donisan, T; Gould, KL; Hassan, S; Iliescu, C; Karimzad, K; Kim, P; Lopez-Mattei, J; Palaskas, N; Sudasena, D | 1 |
| Barbe, M; Berretta, RM; Dunn, J; Duran, JM; Force, T; Gao, E; Gross, P; Houser, SR; Husain, S; Kubo, H; Lal, H; Makarewich, CA; Sharp, TE; Starosta, T; Trappanese, D; Vagnozzi, RJ; Yu, D | 1 |
| Deguchi, T; Horie, K; Kato, T; Kawata, K; Kikuchi, M; Miyazaki, T; Mizutani, K; Nakano, M; Seike, K; Takagi, K; Takai, M; Tsuchiya, T; Ushikoshi, H; Yasuda, M; Yokoi, S | 1 |
| Arima, Y; Fukushima, H; Nakamura, S; Noda, K; Ogawa, H; Oshima, S; Shono, M; Taniguchi, I | 1 |
4 other study(ies) available for sorafenib and Cardiovascular Stroke
| Article | Year |
|---|---|
Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib.
Topics: Adult; Antineoplastic Agents; Cardiotoxicity; Cardiovascular Agents; Coronary Artery Disease; Coronary Restenosis; Defibrillators; Defibrillators, Implantable; Drug-Eluting Stents; Electric Countershock; Endovascular Procedures; Humans; Intra-Aortic Balloon Pumping; Leukemia, Myeloid, Acute; Male; Myocardial Infarction; Peripheral Arterial Disease; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2019 |
Sorafenib cardiotoxicity increases mortality after myocardial infarction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cats; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Heart; In Vitro Techniques; Male; Metoprolol; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib | 2014 |
[Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Myocardial Infarction; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Sorafenib-induced acute myocardial infarction due to coronary artery spasm.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Coronary Vasospasm; Humans; Kidney Neoplasms; Male; Myocardial Infarction; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Sorafenib | 2009 |